Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
posted on 2019-08-28, 10:25authored byJ Floege, SJ Barbour, DC Cattran, JJ Hogan, PH Nachman, SCW Tang, JFM Wetzels, M Cheung, DC Wheeler, WC Winkelmayer, BH Rovin, Conference Participants
The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.
Funding
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.
History
Citation
Kidney International, 2019, 95 (2), pp. 268-280
Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation
SUPPLEMENTARY MATERIAL
Table S1. 2012 Kidney Disease: Improving Global Outcomes (KDIGO)
Glomerulonephritis (GN) guideline recommendations related to IgA
nephropathy: Need to be revisited?
Table S2. 2012 Kidney Disease: Improving Global Outcomes (KDIGO)
Glomerulonephritis (GN) guideline recommendations related to
membranous nephropathy (MN): Need to be revisited?
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.